Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Latest Results: Q3 2015 Quarterly
Piper Jaffray 27th Annual Healthcare Conference
Dec 2 2015 • New York, NY
- Nov 24 2015 8:00 AM EST Cancer Genetics, Inc. to Present at Piper Jaffray 27th Annual Healthcare Conference on December 2nd
- Nov 19 2015 7:30 AM EST Cancer Genetics, Inc. to Receive $1.2 Million In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
- Nov 12 2015 9:38 PM EST Cancer Genetics Announces Closing of $12 Million Public Offering
Cancer Genetics, Inc.
201 Route 17 North
Rutherford, NJ 07070
Life Science Advisors LLC